BioAgilytix specializes in large molecule bioanalysis and has labs in North Carolina’s Research Triangle area and Hamburg, Germany. The company provides PK, immunogenicity, biomarkers, and cell-based assay services.
Sword Bio provides a next-generation detection platform for immunoassays, which, according to the company, can detect picogram levels of analytes.
The companies this week announced a new collaboration in response to a growing customer need for more robust immunoassays used for biomarkers, immunogenicity, and pharmacokinetics (PK).
Afshin Safavi, founder and global chief scientific officer of BioAgilytix, said in a press release: “Sword’s technology will be of great value to BioAgilytix and our customers, as it enables low detection of analytes and gives our team the ability to quickly increase ELISA sensitivity."
“It will further enhance our ability to deliver robust and reliable data from assays that we utilize every day, so that we can help our customers make drug development decisions with confidence," he added.